CME registration deadline: 15th December, 2022

  • Format: Recorded Video Lecture
  • Viewing period with CME points: 15th November 2022 – 15th December 2022
  • Duration: 2 Hours

CME Accredited Colleagues:

  • Hong Kong College of Community Medicine
  • The Hong Kong College of Family Physicians
  • The Hong Kong College of Pathologists
  • Hong Kong College of Paediatricians
  • Hong Kong College of Physicians
  • Hong Kong College of Radiologists
  • The College of Surgeons of Hong Kong
  • Hong Kong College of Obstetricians and Gynaecologists

Organized by 

  • Department of Clinical Oncology,
    School of Clinical Medicine,
    Li Ka Shing Faculty of Medicine,
    University of Hong Kong

Supported by 

  • MEDcentra Technology Limited
  • Hong Kong Precision Oncology Society

Sponsored by

  • Roche Hong Kong Limited


Personalized-Precision Medicine and the N-of-1 Approach for Cancer Therapy

Cancer treatments continue to rapidly evolve from non-specific cytotoxic drugs to highly selective genome, transcriptome, and immune-targeted agents that have transformed the survival outcomes of some malignancies. But our ever-increasing understanding of inter- and intra-tumoral heterogeneity suggest that a more personalized-precision medicine approach to cancer therapy is needed.

However, integrating large amounts of clinical, radiologic, pathologic, and molecular data to develop a treatment plan for patients can be complicated. In recent years there has been an evolution of Molecular Tumor Boards that combine traditional tumor board members with computational biologists, geneticists, and research scientists.

Together, they can better integrate patient and tumor data to develop novel treatment plans by targeting a larger fraction of identified molecular alterations, yielding a higher ‘matching score’, which has been shown to be correlated with significantly improved disease control rates, as well as longer progression-free and overall survival rates, compared to targeting of fewer somatic alterations.

We will discuss how personalized treatment regimens customized combination therapies can be safely and effectively recommended by a Molecular Tumor Board to improve patient survival outcomes.

           Prof. Jason Sicklick

Valuable Information that you should not miss in the Next-Generation Sequencing (NGS) Report

Precision oncology is rapidly developing and integrated into clinical practice. The integration is fueled by the wide adoption of next-generation sequencing (NGS) as a comprehensive genomic panel in the diagnostic workup of cancers.

There is a growing awareness that the interpretation of the NGS results could be highly complex, and if misinterpreted, may lead to undesirable patient outcomes. This necessitates the setup of molecular tumor board (MTB), as an important infrastructure for NGS discussion and treatment recommendations. In this webinar, the essential steps and knowledge involved in navigating the complexity of NGS results would be discussed, and the many important roles of MTB addressed.

           Dr. Lau Kin Sang, Johnny

Case Sharing & MTB Discussion

           Prof. Jason Sicklick         

           Dr. Amy Chang

           Dr. Joseph Siu-Kie AU

           Dr. Lau Kin Sang, Johnny